Following preclinical evaluation of a HER2-specific CAR containing a CD28.ζ signaling domain, Navai et al. (162) conducted a small phase I study (NCT00902044) evaluating the efficacy of HER2-targeted CAR T-cell therapy in combination with lymphodepletion chemotherapy in patients with advanced HER2-positive sarcoma. This evidence concerns the gene ERBB2 and sarcoma.